RS
ALLO icon

R Squared’s Allogene Therapeutics ALLO Stock Holding History

R Squared’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.1K Sell
20,249
-24,996
-55% -$54.9K 0.02% 457
2026
Q1 		$110K Sell
45,245
-40,970
-48% -$82.1K 0.06% 357
2025
Q4 		$118K Buy
86,215
+24,842
+40% +$32.8K 0.06% 399
2025
Q3 		$76.1K Buy
61,373
+28,860
+89% +$34.4K 0.03% 453
2025
Q2 		$36.7K Buy
+32,513
New +$43.2K 0.02% 412
2025
Q1 		– Sell
-110
Closed -$234 – 335
2024
Q4 		$234 Buy
+110
New +$271 ﹤0.01% 1555

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

R Squared's ALLO Position: Q2 2026 in Review

R Squared reduced its Allogene Therapeutics (ALLO) stake by 55% in Q2 2026, selling an estimated $54.9K and leaving 20,249 shares worth $42.1K. The position accounts for 0.02% of the portfolio, ranked #457.

R Squared first reported a position in ALLO in Q4 2024 and has held it in 6 quarters since. The position peaked at $118K in Q4 2025. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • R Squared held 20,249 shares of Allogene Therapeutics worth $42.1K as of Q2 2026.
  • R Squared sold 24,996 Allogene Therapeutics shares in Q2 2026, an estimated $54.9K.
  • Allogene Therapeutics made up 0.02% of R Squared's portfolio in Q2 2026, its #457 holding.
  • R Squared first reported a position in Allogene Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • R Squared's Allogene Therapeutics position peaked at $118K in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.